Skip to content

Esketamine ameliorates depression-like behavior in mice via modulation of the NRG1-ErbB4 pathway.

Hang Yu, Yuqiong Zhu, Jie Wang, Yifan He, Hui Li, Shuxuan Li, Ning Wang, Nuo Chen, Juan Chen, Hongtao Song, Mingjie Zhang, Wenjuan Wang

Frontiers in psychiatry January 1, 2026 DOI: 10.3389/fpsyt.2026.1722336 via PubMed

Summary

AI-generated from the abstract

In a mouse model of depression induced by chronic social defeat stress, susceptible mice showed reduced social interaction, lower sucrose preference, decreased NRG1 protein expression in the prefrontal cortex, and increased immobility time compared to controls. A subanesthetic dose of esketamine increased NRG1 expression in the prefrontal cortex within 30 minutes and improved social interaction and reduced immobility at both 30 minutes and 24 hours post-injection. No significant changes were observed in GAD67 or ErbB4 expression. Esketamine may rapidly improve depressive-like behavior by regulating the NRG1-ErbB4 signaling pathway.

Study at a glance

Characteristics Controlled experiment Peer reviewed
Population Mice subjected to chronic social defeat stress
Intervention Esketamine
Dose subanesthetic dose
Duration 30 minutes and 24 hours post-injection
Topics Esketamine
Keywords Erbb4 Nrg1 Depression disorder
Key finding A subanesthetic dose of esketamine rapidly increases NRG1 expression in the prefrontal cortex and improves depressive-like behaviors in mice susceptible to chronic social defeat stress.

Abstract

Esketamine has a significant and rapid antidepressant effect. Although studies have shown that Neuregulin 1 (NRG1) and it's signaling pathway are associated with depression, the possible regulatory relationship of esketamine on the NRG1-ErbB4 pathway is not yet clear. To induce depressive-like behavior in mice, a Chronic Social Defeat Stress (CSDS) model was established. Behavioral indicators were then employed to assess depression in these mice, categorized into control, susceptible, and resilient groups. Following intraperitoneal injection of a subanesthetic dose of esketamine, behavioral tests were conducted at 30 minutes and 24 hours post-injection to observe any improvements in depressive-like behavior. Additionally, changes in immunofluorescence and protein expression levels of NRG1-ErbB4 and GAD67 in the prefrontal cortex were evaluated. Compared with the control group, the CSDS susceptible group mice showed decreases in social interaction ratio in the contact area, sucrose preference ratio, NRG1 immunofluorescence protein expression in the prefrontal cortex and NRG1 expression in tissue homogenate; showed significant increases in immobility time; the expression of NRG1 decreased;no significant change in GAD67 and ErbB4 expression level. in After 30 minutes of intraperitoneal injection of esketamine, the expression of NRG1 in the prefrontal cortex of susceptible mice increased significantly. no significant change in GAD67 and ErbB4 expression level. After 30 minutes and 24 hours of intraperitoneal injection of esketamine, the social interaction ratio of susceptible group improved compared to the control group, and the duration of forced swimming immobility was significantly shortened. The subanesthetic dose of esketamine may regulate the NRG1-ErbB4 signaling pathway and improve depressive like behavior in mice.

Explore topics

Comments

No comments yet.

Log in to comment